Vaping better at helping smokers quit, study finds
July 14 (UPI) -- Vaping might be more effective than traditional nicotine replacement therapies in helping people quit smoking, a new Australian study says.
Six-month smoking abstinence rates were three times higher among people using flavored nicotine-laced vape devices, compared to those given nicotine gum or lozenges, researchers reported Monday in the Annals of Internal Medicine. Flavored vapes are restricted in the U.S.
"Vaporized nicotine products were more effective than nicotine replacement therapy for smoking cessation," wrote the research team led by Ryan Courtney, an associate professor with the National Drug and Alcohol Research Center at the University of New South Wales in Australia.
For the study, researchers recruited more than 1,000 Australians receiving government assistance and randomly assigned them to vaping or nicotine replacement. All were interested in trying to quit smoking.
The vape group received an eight-week supply of vape juice in tobacco, menthol or fruit flavors, while the nicotine replacement group chose an eight-week supply of gum or lozenges.
All participants also received automated text messages for five weeks that provided behavioral support for their quit attempt, researchers said.
After six months, more than 28% of people in the vape group remained smoke-free, compared with a little under 10% of those in the nicotine gum or lozenge group, the study found.
"In the current trial among people experiencing social disadvantage, vaporized nicotine products with flavor choice had greater effectiveness compared with nicotine replacement therapy gum or lozenge when provided in combination with minimal text-message behavioral support," researchers concluded.
However, researchers noted that further study is needed to make sure that people will remain smoke-free long-term while using a vape device.
It's also unknown whether people are swapping one health risk for another, researchers added.
"Although current evidence suggests switching completely from cigarette smoking to (vaping) reduces health risks, the long-term health effects of vaping are largely unknown and data are emerging that demonstrate vaping can impact cardiovascular health," researchers wrote.
The U.S. government has severely limited the number of flavored tobacco products that are legally available. Kid-friendly flavors like fruit, menthol and dessert, are sold illegally and have been fueling an explosion in retail sales of e-cigarettes, ABC News reported.
More information
Johns Hopkins has more on vaping.
Copyright © 2025 HealthDay. All rights reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
Weight Loss Diet Not Needed With Exercise for Hip OA Pain
A very-low-calorie diet and weight loss combined with exercise does not appear to offer any greater reductions in hip osteoarthritis (OA) pain compared to exercise alone, even in people who are overweight or obese. Overweight and obesity are considered risk factors for hip OA, yet there are conflicting data on whether weight loss reduces the need for hip joint replacement, researchers wrote in their August 4, 2025, report published in Annals of Internal Medicine . In this study, researchers randomly assigned 101 people in Australia with a BMI above 27 to either 1) a dietitian-supported ketogenic very low-calorie diet plus a home-based exercise program supported by regular physiotherapy consultations or 2) the exercise program alone for 6 months . All the participants were aged 50 years or older, had experienced significant hip pain for at least 3 months, and had radiographic evidence of femoral or acetabular osteophytes and joint space narrowing. Despite the very-low-calorie-diet group losing a mean 8.5% more body weight than the exercise-only group, the study found no significant difference between the two groups in the primary outcome of hip pain severity at 6 or 12 months. However, both groups did show a clinically significant reduction in hip pain severity at 6 months: a 2-point reduction on an 11-point scale in the exercise-only group and 2.8-point reduction in the diet plus exercise group. More people in the diet-plus-exercise group achieved a clinically relevant reduction in hip pain severity at 6 months than in the exercise-only group. The study also found that those in the diet group had greater improvements in hip-related quality of life at 6 months compared to the exercise-only group, which persisted to 12 months. Physiotherapist and study co-author Kim Bennell, PhD, director of the Centre for Health, Exercise and Sports Medicine at the University of Melbourne, Australia, said while the association between weight and symptoms or progression was strong with knee OA, there hadn't been many high-quality randomized controlled trials of weight loss for hip OA. 'The knee is not the hip; you can't necessarily generalize results from the knee to the hip,' Bennell told Medscape . 'We thought that it may not be as effective as you find at the knee because there may be different factors driving at the hip; biomechanical factors might be more important.' Could the Results Direct Patients to Seek Surgery Sooner? An accompanying editorial by rheumatologist Gillian Hawker, MD, of Women's College Hospital in Toronto and exercise physiologist Kristine Godziuk, PhD, of the University of California, San Francisco, raised the question of whether the use of pharmacotherapies for weight loss, such as the GLP-1 receptor agonists, might influence outcomes through changes in body composition. Bennell said further studies were needed to explore whether greater weight loss than was achieved in this study might have led to better outcomes and over a longer period. Commenting on the findings, rheumatologist Nancy E. Lane, MD, endowed professor of medicine and rheumatology and director of the Center for Musculoskeletal Health at UC Davis Health, Sacramento, California, said hip OA was much more related to underlying structural abnormalities than other forms of OA. 'There's no therapy that can make it better, because the hip joint, the shape of the hip — either the femoral head or the acetabular cup — is off and it's worn out,' Lane said to Medscape . 'There's no therapy for osteoarthritis of the hip, once it becomes painful.' While weight loss would help to place less stress on the joint, it is a much smaller issue than for other joints, and being overweight in and of itself is not a risk factor for hip replacement, Lane said. 'It was really important to know that this type of exercise and weight loss wasn't going to have an effect on the hip,' she said, pointing out that this knowledge might help people with hip OA to get surgical treatment sooner, rather than being told to lose weight first. 'But to be very clear, that that's not the case in other joints, such as the knee, where these interventions make a difference,' she said.
UPI
8 hours ago
- UPI
Artificial sweetener sucralose may disrupt cancer treatment
Aug. 4 (UPI) -- Findings from a study in mice suggest that using a common artificial sweetener, sucralose, could hamper certain immunotherapy treatments in cancer patients. However, for folks reluctant to give up the ubiquitous sweetener, the same team of scientists may have found a way around the problem: Giving mice a supplement that boosts levels of the natural amino acid arginine appeared to negate the effect. "It's easy to say, 'Stop drinking diet soda,' but when patients are being treated for cancer, they are already dealing with enough, so asking them to drastically alter their diet may not be realistic," said study lead author Abby Overacre, an assistant professor of immunology at the University of Pittsburgh. "We need to meet patients where they are. That's why it's so exciting that arginine supplementation could be a simple approach to counteract the negative effects of sucralose on immunotherapy," she said. Her team published its findings Wednesday in Cancer Discovery. Just how might sucralose disrupt cancer immunotherapies? These treatments include powerful "immune checkpoint inhibitor immunotherapies," such as anti-PD1. This treatment works by boosting the activity of key immune system cells called T cells. T cells need arginine to function effectively if they aim to kill cancer cells, the researchers explained. In the mouse experiments, mice bred to have cancers such as adenocarcinoma or melanoma experienced a shift in their gut microbiomes when sucralose was added to their diets. This led to a flourishing of certain gut bacteria that break down arginine, depleting levels of the amino acid. "When arginine levels were depleted due to sucralose-driven shifts in the microbiome, T cells couldn't function properly," Overacre explained in a university news release. "As a result, immunotherapy wasn't as effective in mice that were fed sucralose." Mice who'd been placed an an anti-PD1 immunotherapy but given sucralose ended up having larger tumors and poorer cancer survival versus those unexposed to sucralose, the team found. But there was a solution: When the researchers gave the mice the supplements arginine or citruline, the potency of immunotherapy returned to normal levels. Of course, experiments in mice don't always pan out in people. However, a follow-up study in cancer patients appeared to support findings observed in mice. The same research team tracked outcomes for 132 patients with either advanced melanomas or lung cancers who had received anti-PD1 immunotherapy alone or in combination with chemotherapy. "We found that sucralose impeded the effectiveness of immunotherapies across a range of cancer types, stages and treatment modalities," said study senior author Dr. Diwakar Davar. "These observations raise the possibility of designing prebiotics, such as targeted nutrient supplementation for patients who consume high levels of sucralose," said Davar, an associate professor of medicine at the university. He said a trial is planned to test the effectiveness of citrulline supplementation in reversing the detrimental effects of sucralose on cancer immunotherapy. As Davar noted, citrulline is thought to boost arginine levels more than giving arginine itself. More information Find out more about anti-PD1 therapies at the U.S. National Cancer Institute. Copyright © 2025 HealthDay. All rights reserved.
UPI
9 hours ago
- UPI
SpaceX lifts 28 Starlink satellites in landmark reusable booster mission
1 of 3 | Poor weather conditions early Monday forced SpaceX to postpone the launch of its Falcon 9 rocket from Launch Complex 40 at the Cape Canaveral Space Force Station in Florida. The booster launched with 28 Starlink satellites on board at 3:57 a.m. local time. Photo by Joe Marino/UPI | License Photo Aug. 4 (UPI) -- SpaceX launched dozens of new Starlink satellites into orbit overnight after initial delays over weather in the company's 69th liftoff this year. The Starlink 10-30 mission saw liftoff at 3:57 a.m. EDT from pad 40 at Cape Canaveral Space Force Station in Florida after its original 2:01 a.m. time slot had to be changed due to persistent storms. The Falcon 9 and its joint Falcon Heavy rocket carried 28 Starlink satellites to its growing constellation of Internet-ready satellite devices. But it marked a milestones for SpaceX with the 450th launch of its flight-proven booster 1080, which flew for its 21st time. Initially there was an 85% chance for favorable weather in the forecast, according to the 45th Weather Squadron. But strong thunderstorms via a low-pressure system hung over the region and temporarily delayed the launch as Tropical Storm Dexter gains strength. A little over 8 minutes after liftoff the B1080 landed on SpaceX's drone ship "Just Read the Instructions" in the Atlantic Ocean in the 131st landing on the drone ship vessel. So far this year SpaceX has launched over 1,650 Starlink satellites in the Elon Musk-run company's bid to expand global Internet access.
